Los Angeles Capital Management
ALLO icon

Los Angeles Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Los Angeles Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.8K Hold
35,970
– – ﹤0.01% 1364
2025
Q4 		$43.5K Hold
35,970
– – ﹤0.01% 1648
2025
Q3 		$44.6K Hold
35,970
– – ﹤0.01% 1340
2025
Q2 		$40.6K Buy
+35,970
New +$47.8K ﹤0.01% 1318
2024
Q3 		– Sell
-125,030
Closed -$291K – 1158
2024
Q2 		$291K Sell
125,030
-35,593
-22% -$105K ﹤0.01% 1021
2024
Q1 		$718K Sell
160,623
-5,355
-3% -$22.3K ﹤0.01% 782
2023
Q4 		$533K Buy
+165,978
New +$471K ﹤0.01% 851
2023
Q3 		– Sell
-41,227
Closed -$205K – 1110
2023
Q2 		$205K Buy
+41,227
New +$223K ﹤0.01% 1116
2021
Q4 		– Sell
-25,283
Closed -$650K – 1384
2021
Q3 		$650K Sell
25,283
-5,230
-17% -$124K ﹤0.01% 938
2021
Q2 		$796K Sell
30,513
-3,087
-9% -$88K ﹤0.01% 953
2021
Q1 		$1.19M Sell
33,600
-10,635
-24% -$359K 0.01% 814
2020
Q4 		$1.12M Sell
44,235
-900
-2% -$29.3K ﹤0.01% 890
2020
Q3 		$1.7M Sell
45,135
-3,420
-7% -$129K 0.01% 611
2020
Q2 		$2.08M Buy
+48,555
New +$1.76M 0.01% 603

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's ALLO Position: Q1 2026 in Review

Los Angeles Capital Management held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 35,970 shares worth $87.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1364.

Los Angeles Capital Management first reported a position in ALLO in Q2 2020 and has held it in 14 quarters since. The position peaked at $2.08M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Los Angeles Capital Management held 35,970 shares of Allogene Therapeutics worth $87.8K as of Q1 2026.
  • Los Angeles Capital Management left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1364 holding.
  • Los Angeles Capital Management first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Los Angeles Capital Management's Allogene Therapeutics position peaked at $2.08M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.